JP4721520B2 - エアロゾル噴射剤に溶解した薬剤 - Google Patents

エアロゾル噴射剤に溶解した薬剤 Download PDF

Info

Publication number
JP4721520B2
JP4721520B2 JP2000606197A JP2000606197A JP4721520B2 JP 4721520 B2 JP4721520 B2 JP 4721520B2 JP 2000606197 A JP2000606197 A JP 2000606197A JP 2000606197 A JP2000606197 A JP 2000606197A JP 4721520 B2 JP4721520 B2 JP 4721520B2
Authority
JP
Japan
Prior art keywords
component
intermediate preparation
propellant
ether
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000606197A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002539240A (ja
JP2002539240A5 (https=
Inventor
モーディ，パンカジュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generex Pharmaceuticals Inc
Original Assignee
Generex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generex Pharmaceuticals Inc filed Critical Generex Pharmaceuticals Inc
Priority claimed from PCT/CA2000/000260 external-priority patent/WO2000056291A1/en
Publication of JP2002539240A publication Critical patent/JP2002539240A/ja
Publication of JP2002539240A5 publication Critical patent/JP2002539240A5/ja
Application granted granted Critical
Publication of JP4721520B2 publication Critical patent/JP4721520B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2000606197A 1999-03-19 2000-03-10 エアロゾル噴射剤に溶解した薬剤 Expired - Fee Related JP4721520B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/272,563 US6350432B1 (en) 1999-03-19 1999-03-19 Pressurized container having an aerosolized pharmaceutical composition
US09/272,563 1999-03-19
US09/388,344 1999-09-03
US09/388,344 US6315984B1 (en) 1999-03-19 1999-09-03 Pressurized container having an aerosolized pharmaceutical composition
PCT/CA2000/000260 WO2000056291A1 (en) 1999-03-19 2000-03-10 Pharmaceutical solubilized in aerosol propellant

Publications (3)

Publication Number Publication Date
JP2002539240A JP2002539240A (ja) 2002-11-19
JP2002539240A5 JP2002539240A5 (https=) 2007-05-10
JP4721520B2 true JP4721520B2 (ja) 2011-07-13

Family

ID=23040339

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000606197A Expired - Fee Related JP4721520B2 (ja) 1999-03-19 2000-03-10 エアロゾル噴射剤に溶解した薬剤

Country Status (2)

Country Link
US (2) US6350432B1 (https=)
JP (1) JP4721520B2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
US20020106331A1 (en) * 2000-12-08 2002-08-08 Joan Rosell Use of electrolytes (ions in solution) to suppress charging of inhalation aerosols
DE10136555A1 (de) * 2001-07-27 2003-02-13 Boehringer Ingelheim Int Optimierte Verfahren zur Bestimmung der Aerosol-Partikelgrößenverteilung und Vorrichtung zur Durchführung derartiger Verfahren
GB0304540D0 (en) * 2003-02-27 2003-04-02 Elan Drug Delivery Ltd Particle formulation and its preparation
ES2660172T3 (es) * 2004-05-19 2018-03-21 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Composición inyectable que comprende desoxicolato de sodio
US7754230B2 (en) * 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
US7540837B2 (en) 2005-10-18 2009-06-02 Varco I/P, Inc. Systems for centrifuge control in response to viscosity and density parameters of drilling fluids
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
BR112012012945A2 (pt) 2009-11-25 2020-12-29 Arisgen Sa Composição de liberação mucosal, seu método de produção, complexo de peptídeo pré-formado, kit e uso de um agente ativo de peptídeo
US20120237492A1 (en) 2011-02-18 2012-09-20 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
US10610512B2 (en) 2014-06-26 2020-04-07 Island Breeze Systems Ca, Llc MDI related products and methods of use
JPWO2016153015A1 (ja) * 2015-03-25 2018-05-10 株式会社ファルマクリエ神戸 高分子薬効成分を含有した口腔内施用物および口腔内への高分子薬効成分の投与方法
CA3026108A1 (en) 2016-06-10 2017-12-14 Clarity Cosmetics Inc. Non-comedogenic hair and scalp care formulations and method for use

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0441421A (ja) * 1990-06-07 1992-02-12 Taisho Pharmaceut Co Ltd 肺吸収組成物
WO1997006813A1 (en) * 1995-08-15 1997-02-27 Asahi Kasei Kogyo Kabushiki Kaisha Mucosal preparation containing physiologically active peptide
WO1997042938A1 (en) * 1996-05-14 1997-11-20 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
WO1998042368A1 (en) * 1997-03-20 1998-10-01 Novo Nordisk A/S Therapeutic powder formulation for pulmonary administration, containing crystalline insulin
WO1999007340A1 (de) * 1997-08-04 1999-02-18 Boehringer Ingelheim Pharma Kg Wässrige aerosolzubereitungen enthaltend biologisch aktive makromoleküle und verfahren zur erzeugung entsprechender aerosole
JP2002532537A (ja) * 1998-12-21 2002-10-02 ジェネレクス ファーマシューティカルズ インコーポレイテッド 肺への薬物送達
JP2003508421A (ja) * 1999-08-31 2003-03-04 ジェネレクス ファーマシューティカルズ インコーポレイテッド 混合ミセル状薬剤の送達システム及び調製方法
JP2003522096A (ja) * 1998-02-10 2003-07-22 ジェネレクス ファーマシューティカルズ インコーポレイテッド 混合ミセル状薬剤の移送システム及び調製方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4582820A (en) 1982-12-23 1986-04-15 Research Corporation Orally administered biologically active peptides and proteins
IL68769A (en) 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
DK179286D0 (da) 1986-04-18 1986-04-18 Nordisk Gentofte Insulinpraeparat
US5690954A (en) 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
US5006343A (en) 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
US5174988A (en) * 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
GB9007052D0 (en) 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
US5230884A (en) 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
IS1796B (is) 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5747445A (en) 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
DK0731688T3 (da) 1993-12-02 2003-06-23 Abbott Lab Aerosol-lægemiddelformuleringer til anvendelse med CFC-frie drivmidler
GB9417524D0 (en) 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6214375B1 (en) * 1996-07-16 2001-04-10 Generex Pharmaceuticals, Inc. Phospholipid formulations
US5898028A (en) 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US6193997B1 (en) * 1998-09-27 2001-02-27 Generex Pharmaceuticals Inc. Proteinic drug delivery system using membrane mimetics
US6271200B1 (en) * 1998-12-21 2001-08-07 Generex Pharmaceuticals Inc. Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0441421A (ja) * 1990-06-07 1992-02-12 Taisho Pharmaceut Co Ltd 肺吸収組成物
WO1997006813A1 (en) * 1995-08-15 1997-02-27 Asahi Kasei Kogyo Kabushiki Kaisha Mucosal preparation containing physiologically active peptide
WO1997042938A1 (en) * 1996-05-14 1997-11-20 Biozone Laboratories, Inc. Delivery of biologically active material in a liposomal formulation for administration into the mouth
WO1998042368A1 (en) * 1997-03-20 1998-10-01 Novo Nordisk A/S Therapeutic powder formulation for pulmonary administration, containing crystalline insulin
WO1999007340A1 (de) * 1997-08-04 1999-02-18 Boehringer Ingelheim Pharma Kg Wässrige aerosolzubereitungen enthaltend biologisch aktive makromoleküle und verfahren zur erzeugung entsprechender aerosole
JP2003522096A (ja) * 1998-02-10 2003-07-22 ジェネレクス ファーマシューティカルズ インコーポレイテッド 混合ミセル状薬剤の移送システム及び調製方法
JP2002532537A (ja) * 1998-12-21 2002-10-02 ジェネレクス ファーマシューティカルズ インコーポレイテッド 肺への薬物送達
JP2003508421A (ja) * 1999-08-31 2003-03-04 ジェネレクス ファーマシューティカルズ インコーポレイテッド 混合ミセル状薬剤の送達システム及び調製方法

Also Published As

Publication number Publication date
JP2002539240A (ja) 2002-11-19
US6350432B1 (en) 2002-02-26
US6315984B1 (en) 2001-11-13

Similar Documents

Publication Publication Date Title
JP3818852B2 (ja) 肺への薬物送達
JP3818851B2 (ja) 口及び肺に適用されるエアロゾル調製物
EP1261320B1 (en) Micellar pharmaceutical compositions for buccal and pulmonary application
CA2410065C (en) Micellar pharmaceutical compositions for buccal and pulmonary application
JP4721520B2 (ja) エアロゾル噴射剤に溶解した薬剤
JP2003508421A (ja) 混合ミセル状薬剤の送達システム及び調製方法
EA003405B1 (ru) Способ и устройство для введения действующего вещества в виде аэрозоля в легкие пациента
JP2003522096A (ja) 混合ミセル状薬剤の移送システム及び調製方法
WO2009015456A1 (en) Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray
US20030157029A1 (en) Methods of administering and enhancing absorption of pharmaceutical agents
CA2364610C (en) Pharmaceutical solubilized in aerosol propellant
AU2003259466B2 (en) Methods of administering and enhancing absorption of pharmaceutical agents
AU2006200276B2 (en) Micellar pharmaceutical compositions for buccal and pulmonary application
Ranade Inhalation therapy: new delivery systems
KR20080071184A (ko) 경구로 흡수되는 약학적 제형 및 투여 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070306

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100810

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101105

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101208

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101224

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110209

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110308

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110405

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140415

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees